Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Some TV commercials would sure catch some eyes.
YUP GLTY Long MNKD going to be a good year.
Accumulation is on the rise.eom
And smarter folks will dump at much higher levels.glty
Free Daily Newsletter subscribe Terms & Conditions Facebook Twitter Google+ RSS
MannKind Sees More Insider Selling
By Jon C. Ogg December 4, 2014 12:10 pm EST
Print Email
inShare
MannKind Corp. (NASDAQ: MNKD) saw its shares trading lower on Thursday, on what was a day with little or no real news from the company. The culprit may simply be insiders selling more shares. One thing that should be pointed out first and foremost is that these shares sold were part of a scheduled insider share sale under the formal Rule 10B5-1 Plan.
The total proceeds between these two insider sales came to more than $1.4 million — versus a market cap of about $2.3 billion. A second issue to consider is that other insiders also sold over 250,000 shares later in November as well.
Diane Palumbo, Vice President of Human Resources, sold some 183,522 shares on December 1 at a volume weight average price (VWAP) of $5.8943, for just over $1 million in total proceeds. She still has 29,105 shares.
Hakam Edstrom, president, sold some 74,668 shares on December 1 at a VWAP of $5.8937 per share, for a total of about $440,000. Edstrom is shown to have 1.047 million shares remaining.
The logic over insider selling is far more complicated than open market share purchases by corporate insiders. The insiders may be doing estate planning, they may be buying a house or there may be myriad other reasons. Again, these two insider sales were under a Rule 10B5-1 Plan, so they are likely less than ominous on the surface. Still, with MannKind shares having been cut in half, and with so many skeptics fighting optimists here, it is easier to see why some investors might wonder about large blocks of stock being sold.
Read more: MannKind Sees More Insider Selling (NASDAQ: MNKD) - 24/7 Wall St. http://247wallst.com/healthcare-business/2014/12/04/mannkind-sees-more-insider-selling/#ixzz3KxFJBtOG
Follow us: @247wallst on Twitter | 247wallst on Facebook
I hope one day MR Mann lives long enough to find a cure for cancer GOD BLESS MR Mann and and have a great thanks giving good luck to you TREND1.
FWIW TREND1
But Alfred Mann's motivations went far deeper than money.
The Los Angeles billionaire already could claim a stunning array of medical advances: His companies had created a rechargeable pacemaker; an implant that enables deaf people to hear; a prosthetic retina that helps blind people see; an insulin pump that transformed the treatment of diabetes; a device that enables amputees to control prosthetic fingers with their brains.
It was 2011, and Mann had his sights on inhaled insulin — a breakthrough that could spare millions of diabetics the pain of billions of daily pinpricks.
I'm trying to help people. How else would I have been able to work until I'm almost 90, if I didn't have something to motivate me?
- Alfred Mann
Mann ordered his executives to cancel all the company's other projects, make painful job cuts and focus on the future of the drug, Afrezza.
The effort paid off. In June, the FDA blessed the drug, which led French pharmaceutical company Sanofi to pay MannKind Corp. $925 million for marketing rights, plus 35% of profits.
The deal could generate billions of dollars for MannKind. But for its chief executive — an 88-year-old physicist, inventor and entrepreneur who has launched 17 companies in five decades — it marks the capstone of a singular crusade.
"I know what motivates him," said Keith Markey, a Griffin Securities analyst who covers MannKind. "He'd like to do as much as he can for humanity.
It's all about the Bass no Treble.you got it Phaeton go MNKD.
The going rate is 15 percent they got double show me a company that got more. GLTY.
FWIW
Insulin is adsorbed onto carrier particles consisting of fumaryl diketopiperazine (FDKP) and polysorbate 80.
AFREZZA Inhalation Powder is a dry powder supplied as 4 unit or 8 unit cartridges. The 4 unit cartridge contains 0.35 mg of insulin. The 8 unit cartridge contains 0.7 mg of insulin.
AFREZZA Inhaler
The AFREZZA Inhaler is breath-powered by the patient. When the patient inhales through the device, the powder is aerosolized and delivered to the lung. The amount of AFREZZA delivered to the lung will depend on individual patient factors.
So am I.
When MNKD starts to move up it's going to be like a freight train.good luck to you 'KingDMC' jmho.
FWIW
This lax attitude toward the disease may explain why nearly 30 percent of Americans who have diabetes don’t realize it, according to a new study in the Annals of Internal Medicine, conducted by Del Rio and other Emory University scientists. They analyzed health data for 29,353 people from the National Health and Nutritional Examination Survey, identifying those with diabetes based on levels of fasting glucose and hemoglobin A1C (an indicator of blood-sugar control).
Overall, about 12 percent of all U.S. adults had diabetes, which translated to 28.4 million people in 2012. Among those, nearly 8 million hadn’t been diagnosed — a stat that’s made all the more alarming by the fact that most regularly went to the doctor: Two-thirds of undiagnosed diabetics had seen a health care provider at least twice in the past year, the study found.
Denise love Maui and love MNKD.GL
How do I even answer a question like that.GLTY
Hope this helps you robin
A live video webcast of the seminar will be available at
2:30 pm CET / 1:30 pm GMT / 8:30 am EST.
The event will be the first in a new series of events focusing on late-stage pipeline assets.
The agenda will consist of several deep dive sessions on new medicines and vaccines that we expect to launch in 2015, such as alirocumab, Dengue vaccine, Toujeo® and Afrezza®. A high level update on the next wave of innovative medicines and vaccines will also be provided.
The presentations will be followed by a Q&A session.
Accumulation on MNKD still moving up. Keep an eye on that.GLTA
Interesting did not know sanofi sold exubera to pfizer
MannKind and Sanofi are set to launch their inhalable insulin product. Approved earlier this year by the FDA, Afrezza is a fast-acting insulin to be taken at mealtimes. The drug is effective for both Type 1 and Type 2 diabetes.
Seven years ago, Pfizer launched Exubera, another inhalable insulin. When Exubera was introduced, it was believed to be a blockbuster product. However, Pfizer abandoned it because the product proved to be clumsy, inconvenient and very expensive. Moreover, the drug that it delivered was less efficient when compared to the injected rapid acting analogs. Pfizer stopped manufacturing the product in 2007, and in the process suffered a financial loss of $2.8 billion. Not only was the drug unable to gain both patient and physician acceptance, there was also an increased risk of lung cancer among its users.
MannKind and Sanofi are confident that Afrezza will not see the same fate. They believe that the two products cannot be compared; Afrezza claims to be different. The product has been produced using a Technosphere formulation technology platform that encompasses the excipient fumaryl diketopiperazine (FDKP). It has a pH of 6.0 and thus aids drug delivery.
It is interesting to note that Sanofi was the company that originally sold Exubera to Pfizer. Now, it has signed a $150 million marketing and commercialising deal with MannKind. The logic behind this step is that Sanofi already knows about Exubera and is in a better position to assess and judge that Afrezza is different from it.
Afrezza is small and elegant and has a PK profile that closely mimics the natural prandial insulin response. While the product may not replace injections, it can still prove to be an alternate way to give diabetics insulin therapy faster.
One surprising aspect of this deal between Sanofi and MannKind is the fact that Sanofi retains 65 percent of all profits while MannKind gets a mere 35 percent, despite putting in years of investment in researching and developing the product. However, since Sanofi will now bear the cost of any additional development and commercialisation. Also, since MannKind is a fairly small company as compared to Sanofi, the partnership may enable it to reach a wider target audience.
The product is expected to be launched in the first quarter of 2015.
Source: In-Pharma Technologist
Image Credit: Wikimedia Commons
Published on : 14/11/2014
- See more at: http://healthmanagement.org/c/pharmacy/news/sanofi-and-mannkind-to-launch-inhalable-insulin#sthash.Mk56pc0l.dpuf
Not at all TREND1 had nothing to with afeeza. GLTY
Fair enough TREND1.
TREND1 you no what nobody no body knows until this drug comes to market you maybe right or I maybe right but know one knows until this drug comes to market.good luck to you and let's see what happens.peace my friend.
Old news TREND1 trying to find what I read earlier.
Market is distorting the reality to scare unseasoned investors with drastic share declines and misinterpretations of the deal
Phaeton I hope it's a high rise building. I will be on it. long MNKD. GLTY
FWIW
$45 billion by 2020.
Facing Lantus' upcoming patent expiration, Sanofi has already partnered withRegeneron (NASDAQ: REGN) to commercialize Regeneron's revolutionary anti-lipid drug alirocumab – a powerful drug that posted excellent phase 3 data in its unparalleled ability to reduce LDL-cholesterol with similar safety yet much better efficacy than the Illustrious Blockbuster drug, Lipitor that recognized more than $12 billion peak revenue for Pfizer. Now with Afrezza on board, Sanofi will not only be replacing Lantus’ upcoming loss in revenues due to its patent's cliff but the French drugs maker will catalyze its next phase of earnings growth.
Investors should note that MannKind partnered up with not just a winner but also one that would enable Afrezza to achieve complete dominance in this diabetes market. Sanofi is a global powerhouse and supreme leader in diabetes that delivered the top prescribed basal (long acting) insulin Lantus for 2013. Backed by recommendations from the American Diabetes Association as the basal insulin of choice, Lantus is widely prescribed in 120 countries delivering more than $6 billion in annual revenues for Sanofi. Now Afrezza has become the chosen one to replace, and probably outperform, Lantus.
360 Biotech's research shows that Afrezza will initially be prescribed as a mealtime insulin but doctors will soon realize its stellar efficacy and safety in combination with Lantus (prescribed at higher doses as seen fit by the clinicians). This will lead to significant improvement in A1c (a monitoring marker for diabetes), and physicians will start to prescribe it off-label for prediabetes or obesity to optimize insulin sensitivity. Another likely scenario is that Sanofi, with its extensive experience, deep pockets, and diabetes expertise, will file for Afrezza's label extension for prediabetes treatment.
Prediabetes is the area commonly overlooked but the statistics show that the market for prediabetes is even larger than diabetes per se. Given the American Diabetes Association pushing for early insulin treatment, it's highly likely that the future trend will be toward treating prediabetes. Hence, the market will be surprised, as Sanofi-MannKind will leverage Afrezza to take complete dominance in the unconquered land of prediabetes and obesity.
Given that obesity, high cholesterol, and insulin resistance tend to occur together in what is known as "co-morbidities," Sanofi's global powerhouse sales/marketing teams could cut down cost and synergistically deliver alirocumab (to treat high LDL-cholesterol) and Afrezza (to nip insulin resistance in the bud to treat both prediabetes and diabetes). It was no coincidence that Sanofi, a world leader with an expert research team and a highly intelligent/strategic board picked Afrezza as the chosen one…the partnership is indeed a match made in heaven! Nonetheless, while the experts at Sanofi and others saw that, Mr. Market is distorting the reality to scare unseasoned investors with drastic share declines and misinterpretations of the deal
Don't have a lot of shares but got in this week.let's see what happens like to add more if things improve. long BKCC.
I can kick myself for not picking some up on the cheap. picked up another hundred shares early today.and feel good about it. long MNKD
Agree with that tyfoidhana not worth the breath that comes out of their mouths. long mnkd
Disgruntled share holders that are pist offed and nothing better to do.JMO GLTY audi65
Agree pappythom at these level or lower you got to put some more money in the game.GLTY.
MannKind Corporation: Why Lantus and Afrezza Do Not Cause Cancer
Published: Saturday, 23 August 2014 12:19 Written by Doctor Hung Tran, MD, MS
Disclosure: We are long on MNKD and we do not have any financial relationship with any company we cover.
360 Catalyst Keys
The ORIGIN trial – studied insulin glargine (Lantus) in patients with Type 2 diabetes and presented at the American Diabetes Association (ADA) in 2013 – proved that insulin does not cause malignancy. The same fallacious notion that Lantus causes cancer or neoplasm now directs toward Afrezza
Critics misapprehended the data (on insulin and cancer) due to the difficulty and often misunderstood relationship between statistical correlation and causality
Patients with Type 2 diabetes often have other coexisting diseases such as obesity, hypertension, and/or hypercholesterolemia, which collectively refer to as "confounders." Obesity is a confounder of interest because there is a plethora of literature proving that obesity increases risk of cancer
The United States Food and Drugs Administration (FDA) has mandatory post-approval surveillance (i.e. phase 4 trials) studies of all drugs and Afrezza is not an exception
Pulmonary hyperplasia is a requisite for lung cancer, but all clinical trials did not show any evidence of hyperplasia. MannKind's clinical trials data proved Afrezza is indeed safe. If hyperplasia occurs, it will occur in patients who participated in the Affinity trials already. Moreover, patients who were on Exubera and then switched to Afrezza, in an ongoing trial, do not exhibit signs and/or symptoms of hyperplasia such as decreasing total lung capacity (TLC), forced expiratory volume (FEV1), force vital capacity (FVC), and etcetera; otherwise, the trial should have been halted
Patients exposed to carcinogens like tobacco smoke are found to have elevated levels of insulin-like growth factors receptors (IGF-Rs) in the lungs, which means carcinogens cause an increased in IGF-R. Hence, IGF-Rs are simply biomarkers produced by cancerous lungs rather than causing lung cancer
The human physiology has evolved over centuries, and natural substances produce by our body (i.e. insulin) do not cause cancers or else, we are already extinct
Agree with you Phaeton every where you read it's doom and gloom you tell right off the bat who the shorters are ain't no secret.I am staying long have a good feeling about this company.GLTY
TREND1 I am sure the FDA would not have approved it if was certain it caused lung cancer. look at cigarettes there something that flying off the shelves and is known to cause lung cancer.I think the benefits out weighs the risk.time will tell.FWIW
TREND1 not to sound sarcastic but me and my eleven year old daughter laugh at some of these drug commercials with these side effects I mean some say may cause death. MNKD should overcome these warnings. my wife just passed away last month of lung cancer at 53 years old but she was a smoker.I hope MNKD can come up with a new cancer drug in the future.GL TREND1.
No I don't TREND1 I don't think anyone can until this drug hit's the market.GLTY TREND1.
FWIW
Afrezza will be priced similarly to some injectable devices, but skeptics say diabetics will still have other options and payers must be convinced to give Afrezza preferential treatment for deciding reimbursement
Sanofi's reasons for inking this deal are bountiful
The industry has come to view inhaled insulin products as risky following the Exubera calamity. And instead, we have seen a bitter competition break out in the basal and fast-acting insulin markets via minimally invasive injectables.
On the basal side, Sanofi pretty much owns the market with Lantus. However, Lantus is set to go off patent protection in February, and major pharmas have been ramping up to launch generic versions. And Lantus makes up roughly 20% of Sanofi's revenue, so it's a pretty big deal for shareholders there.
Sanofi is hoping to replace Lantus with a longer-acting form called Toujeo, but again, Lilly and Novo are hard at work developing competing versions called insulin peglispro and Tresiba, respectively. In sum, Sanofi's 80% market share of the basal insulin market is under serious duress.
By playing the intellectual-property game, Sanofi may be able to fend off competitors long enough to transition most, if not all, patients over to Toujeo down the line. That said, this scenario is far from certain and could result in a massive hit to Sanofi's bottom line.
Is Sanofi hitting its competitors where it hurts with Afrezza?
Sometimes the best defense is a good offense. And that appears to be Sanofi's strategy with Afrezza. While other Big Pharmas may have passed on Afrezza because of the risk involved, I think Sanofi saw an opportunity to hit its chief competitors, Lilly and Novo, in the pocketbook. Lilly and Novo currently dominate the fast-acting insulin market. Taken together, these two injectables and their delivery devices raked in over $7 billion in sales in 2013
If your short mnkd you will be saying ouch soon.GLTY.
No does ty.
Accumulation seems to have a little spike up.